1. Home
  2. CXE vs VRCA Comparison

CXE vs VRCA Comparison

Compare CXE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS High Income Municipal Trust

CXE

MFS High Income Municipal Trust

HOLD

Current Price

$3.65

Market Cap

116.6M

Sector

Finance

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$6.19

Market Cap

137.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXE
VRCA
Founded
1989
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.6M
137.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CXE
VRCA
Price
$3.65
$6.19
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
92.7K
46.4K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
4.36%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
N/A
$35,577,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$94.44
P/E Ratio
$52.14
N/A
Revenue Growth
N/A
370.22
52 Week Low
$3.40
$0.52
52 Week High
$3.88
$9.82

Technical Indicators

Market Signals
Indicator
CXE
VRCA
Relative Strength Index (RSI) 43.95 50.43
Support Level $3.63 $6.15
Resistance Level $3.78 $6.40
Average True Range (ATR) 0.03 0.49
MACD 0.00 0.00
Stochastic Oscillator 44.40 57.58

Price Performance

Historical Comparison
CXE
VRCA

About CXE MFS High Income Municipal Trust

Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: